Crescita Therapeutics Past Earnings Performance
Past criteria checks 0/6
Crescita Therapeutics's earnings have been declining at an average annual rate of -46.6%, while the Pharmaceuticals industry saw earnings growing at 0.03% annually. Revenues have been growing at an average rate of 0.2% per year.
Key information
-46.6%
Earnings growth rate
-46.5%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | 0.2% |
Return on equity | -12.9% |
Net Margin | -13.1% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Crescita Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 18 | -2 | 10 | 1 |
31 Dec 23 | 18 | -2 | 10 | 1 |
30 Sep 23 | 19 | -1 | 10 | 1 |
30 Jun 23 | 22 | 1 | 10 | 1 |
31 Mar 23 | 23 | 1 | 10 | 1 |
31 Dec 22 | 24 | 1 | 11 | 1 |
30 Sep 22 | 25 | 1 | 11 | 1 |
30 Jun 22 | 22 | 0 | 11 | 1 |
31 Mar 22 | 18 | -1 | 10 | 1 |
31 Dec 21 | 17 | -1 | 9 | 1 |
30 Sep 21 | 12 | -3 | 8 | 1 |
30 Jun 21 | 16 | 2 | 8 | 1 |
31 Mar 21 | 15 | 0 | 8 | 1 |
31 Dec 20 | 16 | 0 | 8 | 1 |
30 Sep 20 | 17 | 0 | 8 | 1 |
30 Jun 20 | 14 | -4 | 8 | 1 |
31 Mar 20 | 22 | 1 | 9 | 1 |
31 Dec 19 | 22 | 2 | 8 | 1 |
30 Sep 19 | 25 | 5 | 9 | 2 |
30 Jun 19 | 24 | 6 | 9 | 1 |
31 Mar 19 | 17 | 3 | 8 | 1 |
31 Dec 18 | 17 | 2 | 9 | 1 |
30 Sep 18 | 13 | -9 | 9 | 2 |
30 Jun 18 | 11 | -10 | 10 | 2 |
31 Mar 18 | 14 | -9 | 11 | 1 |
31 Dec 17 | 12 | -11 | 12 | 1 |
30 Sep 17 | 12 | -8 | 13 | 0 |
30 Jun 17 | 10 | -10 | 13 | 0 |
31 Mar 17 | 5 | -13 | 12 | 0 |
31 Dec 16 | 4 | -15 | 12 | 0 |
30 Sep 16 | 1 | -12 | 11 | 0 |
30 Jun 16 | 0 | -7 | 10 | 0 |
31 Mar 16 | 0 | -10 | 9 | 0 |
31 Dec 15 | 0 | -7 | 6 | 0 |
31 Dec 14 | 1 | -15 | 7 | 0 |
Quality Earnings: CRRT.F is currently unprofitable.
Growing Profit Margin: CRRT.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CRRT.F is unprofitable, and losses have increased over the past 5 years at a rate of 46.6% per year.
Accelerating Growth: Unable to compare CRRT.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CRRT.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.5%).
Return on Equity
High ROE: CRRT.F has a negative Return on Equity (-12.89%), as it is currently unprofitable.